Penumbra
PEN
316.35
-0.70
-0.22%
Penumbra
US · PEN
#1275 by market cap
Listed 2015
316.35
-0.70
-0.22%
Live - 5344 symbols - heartbeat 198s ago
· 2026-10-07 19:54
After-hours
316.35
0.00%
- Market cap
- 12.46B
- P/E (TTM)i
- 77.73
- P/Bi
- 8.14
- EPSi
- 4.52
- Div yieldi
- 0.00%
- 52W posi
- 67%
Reader sentiment
Are you bullish or bearish on PEN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 20.71, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +17.50% YoY
Margins
- Gross margin
- 67.14%
- Operating margin
- 13.48%
- Net margin
- 12.66%
Key ratios & quality
- Altman Z-Scorei
- 20.71
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 444.94M | 547.41M | 560.41M | 747.59M | 847.13M | 1.06B | 1.19B | 1.40B |
| Gross profit | 292.53M | 371.96M | 338.18M | 475.38M | 535.21M | 682.64M | 755.00M | 942.44M |
| Selling & admin expenses | 226.39M | 272.73M | 287.07M | 378.33M | 449.72M | 506.45M | 573.99M | 663.42M |
| Research & development | 36.17M | 51.72M | 90.05M | 104.55M | 79.41M | 84.42M | 94.78M | 89.77M |
| Operating profit | 29.98M | 47.51M | -38.94M | -7.50M | 6.08M | 91.77M | 86.22M | 189.25M |
| Pretax profit | 1.61M | 50.14M | -38.02M | -10.50M | 3.89M | 79.65M | 20.87M | 205.13M |
| Tax | -4.40M | 3.13M | -18.76M | -13.13M | 5.89M | -11.30M | 6.86M | 27.44M |
| Net profit | 2.91M | 47.00M | -19.26M | 2.62M | -2.00M | 90.95M | 14.01M | 177.69M |
| Basic EPS | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 5 |
| Diluted EPS | 0.18 | 1.34 | -0.44 | 0.14 | -0.05 | 2.32 | 0.36 | 4.52 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 324.14M | 339.46M | 354.69M | 385.39M | 374.76M | 390.05M |
| Gross profit | 215.88M | 224.01M | 240.42M | 262.13M | 253.41M | 264.94M |
| Selling & admin expenses | 153.46M | 159.96M | 168.90M | 181.10M | 192.80M | 198.51M |
| Research & development | 22.08M | 23.22M | 22.68M | 21.79M | 22.38M | 25.40M |
| Operating profit | 40.35M | 40.83M | 48.84M | 59.23M | 38.23M | 41.04M |
| Pretax profit | 43.86M | 45.31M | 52.33M | 63.63M | 41.69M | 46.19M |
| Tax | 4.64M | 40.00K | 6.47M | 16.29M | 9.10M | 11.38M |
| Net profit | 39.22M | 45.27M | 45.85M | 47.34M | 32.58M | 34.81M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 1.00 | 1.15 | 1.17 | 1.20 | 0.82 | 0.88 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 410.73M | 463.13M | 617.70M | 681.47M | 755.70M | 915.40M | 951.13M | 1.22B |
| Cash & ST investments | 200.89M | 189.39M | 264.83M | 254.88M | 188.03M | 289.19M | 340.13M | 544.82M |
| Inventory | 115.74M | 152.99M | 219.53M | 263.50M | 334.01M | 388.02M | 406.74M | 431.55M |
| Total assets | 515.01M | 665.90M | 822.98M | 1.24B | 1.37B | 1.56B | 1.53B | 1.83B |
| Total current liabilities | 66.06M | 91.05M | 105.93M | 123.20M | 144.93M | 151.14M | 158.35M | 183.13M |
| Short-term debt | -- | 8.31M | 6.03M | 9.98M | 11.95M | 13.43M | 14.59M | 16.23M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 92,591,000.00 | 180,288,000.00 | 185,195,000.00 | 290,323,000.00 | 372,028,000.00 | 377,361,000.00 | 382,250,000.00 | 398,916,000.00 |
| Total equity | 422.42M | 485.61M | 637.79M | 953.93M | 998.86M | 1.18B | 1.15B | 1.43B |
| Retained earnings | 9.06M | 57.52M | 40.62M | 45.91M | 43.90M | 134.86M | 60.00M | 237.69M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 999.71M | 1.07B | 1.14B | 1.22B | 1.28B | 1.34B |
| Cash & ST investments | 378.85M | 424.56M | 470.30M | 544.82M | 615.66M | 658.80M |
| Inventory | 415.86M | 427.63M | 432.37M | 431.55M | 438.54M | 442.65M |
| Total assets | 1.59B | 1.67B | 1.74B | 1.83B | 1.90B | 1.97B |
| Total current liabilities | 158.63M | 157.76M | 169.60M | 183.13M | 211.73M | 233.78M |
| Short-term debt | 14.80M | 15.25M | 15.51M | 16.23M | 16.53M | 16.78M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 380,425,000.00 | 380,858,000.00 | 385,673,000.00 | 398,916,000.00 | 424,626,000.00 | 443,957,000.00 |
| Total equity | 1.21B | 1.29B | 1.36B | 1.43B | 1.47B | 1.53B |
| Retained earnings | 99.23M | 144.50M | 190.35M | 237.69M | 270.28M | 305.09M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 28.81M | 26.65M | -33.24M | 9.50M | -55.66M | 97.33M | 168.48M | 238.66M |
| Depreciation & amortization | 6.17M | 8.10M | 12.89M | 16.41M | 24.32M | 27.26M | 23.70M | 17.47M |
| Free cash flow | 19.21M | 4.54M | -58.00M | -11.68M | -74.96M | 82.12M | 147.30M | 174.93M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 134.76M | 0 | 0 | 0 | -100.39M | 0 |
| Ending cash balance | 67.85M | 72.78M | 69.67M | 59.38M | 69.86M | 167.49M | 324.40M | 186.90M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 48.97M | 44.95M | 58.26M | 86.48M | 86.97M | 46.08M |
| Depreciation & amortization | 5.02M | 5.51M | 2.49M | 4.46M | 4.57M | 5.62M |
| Free cash flow | 35.50M | 29.37M | 42.01M | 68.05M | 73.30M | 32.54M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 376.05M | 421.77M | 321.03M | 186.90M | 241.29M | 205.27M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 1.60 | 10.67 | -2.79 | 0.66 | -0.21 | 8.35 | 1.20 | 13.78 |
| ROA %i | 1.33 | 8.21 | -2.11 | 0.51 | -0.15 | 6.21 | 0.91 | 10.58 |
| ROIC %i | 1.60 | 9.03 | -2.58 | 0.50 | -0.18 | 6.57 | 0.41 | 10.90 |
| 5-year avg ROE %i | -- | 4.12 | 3.36 | 2.31 | 1.99 | 3.34 | 1.45 | 4.76 |
| EBIT margin %i | 6.74 | 8.68 | -6.95 | -1.00 | 0.72 | 7.69 | 1.87 | 14.71 |
| FCF / sales %i | 4.32 | 0.83 | -- | -- | -- | 7.76 | 12.33 | 12.46 |
| Current ratioi | 6.22 | 5.09 | 5.83 | 5.53 | 5.21 | 6.06 | 6.01 | 6.64 |
| Quick ratioi | 4.28 | 3.24 | 3.58 | 3.16 | 2.70 | 3.25 | 3.21 | 4.01 |
| Debt / assetsi | 0.00 | 12.36 | 9.39 | 13.95 | 17.20 | 15.06 | 14.57 | 12.03 |
| LT debt / equityi | -- | 15.23 | 11.11 | 17.15 | 22.41 | 18.74 | 18.14 | 14.25 |
| Interest coveragei | -- | -- | -- | -- | -- | 46.80 | 15.72 | 157.46 |
| Revenue CAGR (3Y) %i | 33.72 | 27.63 | 18.86 | 18.88 | 15.67 | 23.61 | 16.91 | 18.33 |
| Net income CAGR (3Y) %i | 40.80 | 48.44 | -- | -7.15 | -- | -- | 38.41 | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 3.50 | 12.03 | 13.32 | 13.78 | 12.73 | 11.37 |
| ROA %i | 2.66 | 9.20 | 10.18 | 10.58 | 9.80 | 8.80 |
| ROIC %i | 2.21 | 9.42 | 10.45 | 10.90 | 10.06 | 8.97 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 4.15 | 13.64 | 14.03 | 14.71 | 14.05 | 13.63 |
| FCF / sales %i | 12.12 | 12.63 | 11.44 | 12.46 | 14.63 | 14.35 |
| Current ratioi | 6.30 | 6.75 | 6.73 | 6.64 | 6.02 | 5.75 |
| Quick ratioi | 3.45 | 3.80 | 3.85 | 4.01 | 3.77 | 3.63 |
| Debt / assetsi | 13.85 | 13.17 | 12.44 | 12.03 | 11.39 | 10.77 |
| LT debt / equityi | 16.97 | 15.86 | 14.83 | 14.25 | 13.55 | 12.80 |
| Interest coveragei | 38.44 | 133.08 | 142.32 | 157.46 | 156.40 | 157.91 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Thrombectomy is the largest reported line at 66.40% of revenue, across 2 reported segments.
- Embolization and Access follows at 33.60%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Thrombectomy66.40%
Embolization and Access33.60%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.